Available for oral or IV administration The first and only 5-HT3 and NK-1 combination agent approved for both acute and delayed CINV1,2

A single dose of AKYNZEO® with dexamethasone prevents both acute and delayed chemotherapy-induced nausea and vomiting (CINV) for 5 days

Efficacy 2
Pathways 1
Dose 1

In highly emetogenic chemotherapy, 90% complete response in the AKYNZEO capsules arm (n=135) vs 77% in the palonosetron arm (n=136) (P=.003). Primary endpoint: complete response in overall phase 0–120 hours (complete response was no emesis and no use of rescue medication for 5 days across both acute and delayed CINV)1